0001562180-24-004026.txt : 20240514 0001562180-24-004026.hdr.sgml : 20240514 20240514160525 ACCESSION NUMBER: 0001562180-24-004026 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240513 FILED AS OF DATE: 20240514 DATE AS OF CHANGE: 20240514 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Hadas Nicole R. CENTRAL INDEX KEY: 0001602396 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36352 FILM NUMBER: 24944212 MAIL ADDRESS: STREET 1: 20 PILGRAM DRIVE CITY: WINCHESTER STATE: MA ZIP: 01890 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Akebia Therapeutics, Inc. CENTRAL INDEX KEY: 0001517022 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 208756903 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 245 FIRST STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-871-2098 MAIL ADDRESS: STREET 1: 245 FIRST STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 4 1 primarydocument.xml PRIMARY DOCUMENT X0508 4 2024-05-13 false 0001517022 Akebia Therapeutics, Inc. AKBA 0001602396 Hadas Nicole R. C/O AKEBIA THERAPEUTICS, INC. 245 FIRST STREET CAMBRIDGE MA 02142 false true false false SVP, Chief Legal Officer true Common Stock 2024-05-13 4 S false 12016.00 1.26 D 651243.00 D This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on May 12, 2023. This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2023. /s/ Carolyn Rucci, attorney-in-fact for Nicole R. Hadas 2024-05-14